Vanguard S&P 500 Growth Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $85.25, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VOOG | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $85.42 | $164.28 |
52-Week Low | $65.32 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
VOOG trades at $85.05, down 0.18% on the day but near 52-week highs, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent news highlights institutional accumulation and strong growth ETF comparisons, though RSI levels suggest potential overbought conditions. The fund focuses on large-cap growth stocks with low expense ratios, benefiting from tech sector leadership.
Outlook remains positive due to institutional inflows and growth exposure, but risks include tech concentration and market volatility. The fund's low costs and historical performance support long-term growth appeal, though investors should monitor valuation metrics amid elevated levels.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →